Literature DB >> 15541006

Sharing of polyglutamine localization by the neuronal nucleus and cytoplasm in CAG-repeat diseases.

M Yamada1, C-F Tan, C Inenaga, S Tsuji, H Takahashi.   

Abstract

The expansion of a trinucleotide cytosine adenine and guanine (CAG) repeat that codes for polyglutamine is a common gene mutation in the family of hereditary neurodegenerative diseases that includes Machado-Joseph disease (MJD) and dentatorubral-pallidoluysian atrophy (DRPLA). The presence of ubiquitinated neuronal intranuclear inclusions (NIIs) has been recognized as a neuropathological hallmark of these diseases, although the significance of NIIs in the pathogenesis remains a matter of controversy. In a previous study of DRPLA, we proposed that intranuclear diffuse accumulation of mutant proteins is another pathological characteristic of neurones, and that the variable prevalence of this characteristic may be relevant to the variation of clinical symptoms in patients with different repeat sizes. Recently, we also disclosed that polyglutamine tracts are localized in a subset of lysosomes in affected neurones. The present immunohistochemical study of autopsied MJD and DRPLA brains shows that the nucleus and cytoplasm of affected neurones share the subcellular distribution of expanded polyglutamine tracts, the pattern of distribution being specific to each diseased brain. The results suggest that in CAG-repeat diseases, mutant proteins are involved in both the ubiquitin/proteasome and endosomal/lysosomal pathways for protein degradation in different intraneuronal compartments, where their accumulation may exert distinct influences on neuronal physiology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541006     DOI: 10.1111/j.1365-2990.2004.00583.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  12 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  Machado-Joseph Disease: from first descriptions to new perspectives.

Authors:  Conceição Bettencourt; Manuela Lima
Journal:  Orphanet J Rare Dis       Date:  2011-06-02       Impact factor: 4.123

Review 3.  Pathological accumulation of atrophin-1 in dentatorubralpallidoluysian atrophy.

Authors:  Yasuyo Suzuki; Ikuru Yazawa
Journal:  Int J Clin Exp Pathol       Date:  2011-04-25

4.  Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.

Authors:  Maria do Carmo Costa; Naila S Ashraf; Svetlana Fischer; Yemen Yang; Emily Schapka; Gnanada Joshi; Thomas J McQuade; Rahil M Dharia; Mark Dulchavsky; Michelle Ouyang; David Cook; Duxin Sun; Martha J Larsen; Jason E Gestwicki; Sokol V Todi; Magdalena I Ivanova; Henry L Paulson
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

5.  Distribution and pattern of pathology in subjects with familial or sporadic late-onset cerebellar ataxia as assessed by p62/sequestosome immunohistochemistry.

Authors:  Maria Pikkarainen; Päivi Hartikainen; Hilkka Soininen; Irina Alafuzoff
Journal:  Cerebellum       Date:  2011-12       Impact factor: 3.847

Review 6.  SCA3: neurological features, pathogenesis and animal models.

Authors:  Olaf Riess; Udo Rüb; Annalisa Pastore; Peter Bauer; Ludger Schöls
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

7.  Lithium chloride alleviates neurodegeneration partly by inhibiting activity of GSK3β in a SCA3 Drosophila model.

Authors:  Dan-Dan Jia; Li Zhang; Zhao Chen; Chun-Rong Wang; Feng-Zhen Huang; Ran-Hui Duan; Kun Xia; Bei-Sha Tang; Hong Jiang
Journal:  Cerebellum       Date:  2013-12       Impact factor: 3.847

8.  White matter damage is related to ataxia severity in SCA3.

Authors:  J-S Kang; J C Klein; S Baudrexel; R Deichmann; D Nolte; R Hilker
Journal:  J Neurol       Date:  2013-11-23       Impact factor: 4.849

9.  Change in the cortical complexity of spinocerebellar ataxia type 3 appears earlier than clinical symptoms.

Authors:  Tzu-Yun Wang; Chii-Wen Jao; Bing-Wen Soong; Hsiu-Mei Wu; Kuo-Kai Shyu; Po-Shan Wang; Yu-Te Wu
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

10.  CAG repeat length does not associate with the rate of cerebellar degeneration in spinocerebellar ataxia type 3.

Authors:  Shang-Ran Huang; Yu-Te Wu; Chii-Wen Jao; Bing-Wen Soong; Jiing-Feng Lirng; Hsiu-Mei Wu; Po-Shan Wang
Journal:  Neuroimage Clin       Date:  2016-11-10       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.